

DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe

Mehdi Tafti, PhD^{1,2}; Hyun Hor, MD, PhD^{1,3}; Yves Dauvilliers, MD, PhD^{4,5}; Gert J. Lammers, MD, PhD^{6,7}; Sebastiaan Overeem, MD, PhD⁸; Geert Mayer, MD⁹; Sirous Javidi, MD⁹; Alex Iranzo, MD¹⁰; Joan Santamaria, MD¹⁰; Rosa Peraita-Adrados, MD¹¹; José L. Vicario, PhD¹²; Isabelle Arnulf, MD, PhD¹³; Giuseppe Plazzi, MD, PhD¹⁴; Sophie Bayard, PhD^{4,5}; Francesca Poli, MD, PhD¹⁴; Fabio Pizza, MD, PhD¹⁴; Peter Geisler, MD¹⁵; Aleksandra Wierzbicka, MD¹⁶; Claudio L. Bassetti, MD¹⁷; Johannes Mathis, MD¹⁷; Michel Lecendreux, MD¹⁸; Claire E.H.M. Donjacour, MD⁶; Astrid van der Heide, MD⁶; Raphaël Heinzer, MD²; José Haba-Rubio, MD²; Eva Feketeova, MD¹⁹; Birgit Högl, MD²⁰; Birgit Frauscher, MD²⁰; Antonio Benetó, MD²¹; Ramin Khatami, MD²²; Francesca Cañellas, MD²³; Corinne Pfister, MSc¹; Sabine Scholz⁵; Michel Billiard, MD⁵; Christian R. Baumann, MD²⁴; Guadalupe Ercilla, MD²⁵; Willem Verduijn, BSc²⁶; Frans H.J. Claas, PhD²⁶; Valérie Dubois, MD²⁷; Jacek Nowak, PhD²⁸; Hans-Peter Eberhard, PhD²⁹; Sylvain Pradervand, PhD^{30,31}; Charlotte N. Hor, PhD³; Manuela Testi, PhD³²; Jean-Marie Tiercy, PhD³³; Zoltán Kutalik, PhD^{31,34,35}; on Behalf of the European Narcolepsy Network (EU-NN)

Author affiliations list with corresponding numbers immediately follows paper.

Study Objective: Prior research has identified five common genetic variants associated with narcolepsy with cataplexy in Caucasian patients. To replicate and/or extend these findings, we have tested *HLA-DQB1*, the previously identified 5 variants, and 10 other potential variants in a large European sample of narcolepsy with cataplexy subjects.

Design: Retrospective case-control study.

Setting: A recent study showed that over 76% of significant genome-wide association variants lie within DNase I hypersensitive sites (DHSs). From our previous GWAS, we identified 30 single nucleotide polymorphisms (SNPs) with $P < 10^{-4}$ mapping to DHSs. Ten SNPs tagging these sites, *HLA-DQB1*, and all previously reported SNPs significantly associated with narcolepsy were tested for replication.

Patients and Participants: For GWAS, 1,261 narcolepsy patients and 1,422 *HLA-DQB1*06:02*-matched controls were included. For HLA study, 1,218 patients and 3,541 controls were included.

Measurements and Results: None of the top variants within DHSs were replicated. Out of the five previously reported SNPs, only *rs2858884* within the HLA region ($P < 2 \times 10^{-9}$) and *rs1154155* within the *TRA* locus ($P < 2 \times 10^{-8}$) replicated. *DQB1* typing confirmed that *DQB1*06:02* confers an extraordinary risk (odds ratio 251). Four protective alleles (*DQB1*06:03*, odds ratio 0.17, *DQB1*05:01*, odds ratio 0.56, *DQB1*06:09* odds ratio 0.21, *DQB1*02* odds ratio 0.76) were also identified.

Conclusion: An overwhelming portion of genetic risk for narcolepsy with cataplexy is found at *DQB1* locus. Since *DQB1*06:02* positive subjects are at 251-fold increase in risk for narcolepsy, and all recent cases of narcolepsy after H1N1 vaccination are positive for this allele, *DQB1* genotyping may be relevant to public health policy.

Keywords: Autoimmunity, GWAS, H1N1 vaccination, genetics

Citation: Tafti M; Hor H; Dauvilliers Y; Lammers GJ; Overeem S; Mayer G; Javidi S; Iranzo A; Santamaria J; Peraita-Adrados R; Vicario JL; Arnulf I; Plazzi G; Bayard S; Poli F; Pizza F; Geisler P; Wierzbicka A; Bassetti CL; Mathis J; Lecendreux M; Donjacour CE; van der Heide A; Heinzer R; Haba-Rubio J; Feketeova E; Högl B; Frauscher B; Benetó A; Khatami R; Cañellas F; Pfister C; Scholz S; Billiard M; Baumann CR; Ercilla G; Verduijn W; Claas FH; Dubois V; Nowak J; Eberhard HP; Pradervand S; Hor CN; Testi M; Tiercy JM; Kutalik Z; on Behalf of the European Narcolepsy Network (EU-NN). *DQB1* locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. *SLEEP* 2014;37(1):19-25.

INTRODUCTION

Narcolepsy with cataplexy (hereinafter “narcolepsy”) is a disabling and chronic sleep disorder characterized by irresistible sleep episodes and cataplexy (muscle atonia induced by strong emotions).^{1,2} The genetics of narcolepsy is complex but includes the strongest association ever reported with a single *HLA-DQB1* allele (*DQB1*06:02*).³ Because of the discovery of the HLA association, narcolepsy is believed to be an autoimmune disease. The discovery of hypocretin (orexin) deficiency in narcolepsy with cataplexy^{4,5} raised the possibility that hypothalamic hypocretin-producing neurons might be the target of an autoimmune attack, motivating the search for potential genetic mechanisms.

The first genome-wide association study (GWAS) in narcolepsy with European ancestry found a strong association with the T-cell receptor alpha locus (*TRA*), independent of the HLA.⁶ Our previous GWAS found a significant protective HLA variant.⁷ Another GWAS found evidence for association with *P2RY11*, although with a modest increase in risk (OR = 1.28).⁸ More recently, the autoimmune hypothesis was strengthened by finding circulating auto-antibodies against Tribbles homolog 2 (TRIB2), especially close to the disease onset,⁹⁻¹¹ a surge of newly diagnosed cases of narcolepsy in young people following the 2009 H1N1 vaccination,¹²⁻¹⁵ and the discovery of associations with common variants in *CTSH* and *TNFSF4*, two other immune-related genes.¹⁶

Narcolepsy with cataplexy being a rare disease (prevalence = 0.02%-0.05%), studies including larger populations to increase the statistical power to detect small effect size variants are unlikely to become available in the near future. We therefore performed a modified GWAS replication study in 1,261 European narcolepsy patients and 1,422 *HLA-DQB1*06:02*-matched controls.

Submitted for publication July, 2013

Submitted in final revised form November, 2013

Accepted for publication November, 2013

Address correspondence to: Prof. Mehdi Tafti, Center for Integrative Genomics, University of Lausanne, Génopode, 1015 Lausanne, Switzerland; Tel: +4121 682 3971; Fax: +4121 692 3965; E-mail: Mehdi.tafti@unil.ch

METHODS

Patients and Controls

Informed consent according to each country's ethics institution was obtained from all subjects, and the experimental protocols were approved by the Lausanne (CHUV) ethical committee.

Samples of patients and controls used for discovery GWAS were described previously⁷ and included 562 HLA-*DQB1**06:02 positive narcolepsy with cataplexy patients and 702 origin-matched and HLA-*DQB1**06:02 positive controls of European ancestry. Replication samples included 699 HLA-*DQB1**06:02 positive narcolepsy with cataplexy patients and 720 origin-matched and HLA-*DQB1**06:02 positive healthy controls of European ancestry. All patients were diagnosed according to the International Classification of Sleep Disorders.¹⁷ The origin of patients was: NL: Dutch, DE: German + Austrian, PL: Polish + Slovak, FR: French, SP: Spanish, CH: Swiss, and IT: Italian. Controls were recruited from Dutch, German, Polish, French, Spanish, Swiss, and Italian general populations.

For HLA analysis and estimation of risk for each *DQB1* allele, all centers were required to include any documented *DQB1**06:02 negative patient available. Only *DQB1**06:02 negative patients with low (< 110 pg/mL) or undetectable (< 40 pg/mL) cerebrospinal fluid (CSF) hypocretin-1 were included in the final analysis (N = 20). Hypocretin-1 levels were also available in 294 *DQB1**06:02 positive patients, among whom 252 had undetectable and 31 low levels.² In total, *DQB1* typing was available in 1,218 patients and 3,541 country-matched controls (see Table 2).

SNP and HLA Genotyping

SNP genotyping was performed by KBiosciences (UK) using fluorescence-based competitive allele-specific PCR. High-resolution HLA-*DQB1* genotyping was performed either by reverse sequence-specific oligonucleotide (SSO) or direct sequencing methods by each country's accredited HLA laboratories, according to standard protocols.

Exome Sequencing

Genomic DNA was fragmented with a Covaris S2 sonicator (Covaris, Inc.) to obtain DNA fragments with a homogeneous size distribution having a maximum at 180-200 base pairs. Preparation of the exome enriched, barcoded sequencing libraries was performed using Agilent SureSelect Human All Exon v3 kit. Libraries were sequenced on Illumina HiSeq 2000, generating 100 bp paired-end reads. Purity filtered reads were aligned to the human genome (assembly hg19).

Data Analysis

SNP analysis was performed by logistic regression. All other individual frequency comparisons for HLA alleles were performed by Mantel-Haenszel test and meta-analyzed by the same procedure, using the meta.MH function in R. In order to account for the number of *DQB1* alleles tested, we applied Bonferroni correction (n = 14); thus nominal P values below $\alpha = 0.0036$ are declared to be significant. To determine which haplotypes confer risk (provide protection) independently of

each other, we adapted a step-wise procedure.¹⁸ In each iteration, carriers of the most significantly associated haplotype are removed and the association test (for each remaining haplotype) is repeated for the remaining individuals.

RESULTS

Given that a large number of significant GWAS variants lie within gene regulatory rather than protein coding regions, a recent study found that over 76% of GWAS significant hits map within regulatory regions defined by DNase I hypersensitive sites (DHSs).¹⁹ This suggests that variants within these regulatory regions have a substantially higher probability of showing significant associations. To verify if additional variants associated with narcolepsy can be found, we have mapped all suggestively significant SNPs ($P < 10^{-4}$) from our original GWAS⁷ to DHSs and attempted replication of these top hits in an independent European narcolepsy population: 503 SNPs were found with a P value < 10^{-4} . Mapping these SNPs to DHSs indicated that only 41 (8.15%) were within these regulatory sites. Among these, 10 mapped within the HLA class II region and 3 within the *TRA* locus, for which significant associations with narcolepsy were already reported. The remaining 28 SNPs could be tagged by 10 SNPs. The two previous significant SNPs, *rs2858884* within the HLA region and *rs1154155* within the *TRA* locus, were also included. Among other significant hits reported recently, *rs7553711* within *TNFSF4* and *rs2305795* within *P2RY11* were assessed in our original GWAS and selected for replication. Because the genotypes for the two others (*rs34593439* and *rs34843303* located in intron 1 of *CTSH*) were not available in our discovery analysis, we selected *rs12148472* ($r^2 = 0.93$ with *rs34593439* and $r^2 = 0.95$ with *rs34843303*) as a proxy for this association. Replication samples included 699 narcolepsy patients and 720 HLA-matched controls.

SNPs *rs2858884* (replication $P = 6.40 \times 10^{-4}$, meta-analysis $P = 1.03 \times 10^{-9}$) within the HLA region and *rs1154155* (replication $P = 2.12 \times 10^{-5}$, meta-analysis $P = 1.56 \times 10^{-8}$) within the *TRA* locus were successfully replicated as expected (Table 1). None of the other SNPs withstood the Bonferroni correction. Nevertheless, *rs2305795* within *P2RY11* had a nominal replication $P = 4.70 \times 10^{-3}$, *rs12148472* within *CTSH* $P = 0.017$, and *rs7553711* within *TNFSF4* $P = 0.022$. The last two SNPs were recently reported in an international study in which 584 of our patients were included.¹⁶ Re-analyzing our data without these 584 overlapping patients showed a very similar trend (Table S1).

SNP *rs2858884*, as in our first GWAS, confers protection against narcolepsy (OR = 0.56, 95%CI = 0.47-0.67), even if cases and controls were matched for at least one *DQB1**06:02 allele, strongly suggesting that some *trans DQB1* alleles are protective. HLA alleles frequency distribution shows slight but significant differences among European countries. To find which *trans DQB1* alleles are associated with protection against narcolepsy, we compared patients to healthy controls of the same country of origin. Although *DQB1**06:02 is the most important susceptibility marker in narcolepsy, this association is believed to be neither necessary nor sufficient, because up to 30% of the general population may carry this allele and 5% to 15% of narcolepsy patients may not carry it. We first reassessed the exact number of *DQB1**06:02 negative patients in each country. Table 2 shows the frequency of *DQB1**06:02 positive and negative cases

Table 1—Replication results for SNPs mapping within the DHSs and SNPs already reported as significantly associated with narcolepsy^{6,16}

rs#	Allele	Chr	Pos	AF_C1:AF_N1	OR1[95%CI]	p1	n1	AF_C2:AF_N2	OR2[95%CI]	p2	n2	OR-Meta[95%CI]	pMeta	nMeta
rs2858884	C	6	32808061	0.219:0.100	0.48[0.37-0.62]	4.65E-08	562:702	0.161:0.114	0.69[0.55-0.85]	6.40E-04	656:697	0.59[0.50-0.62]	1.03E-09	1218:1399
rs1154155	T	14	22072524	0.859:0.801	0.65[0.52-0.81]	1.92E-04	562:702	0.835:0.769	0.66[0.55-0.80]	2.12E-05	665:700	0.66[0.57-0.81]	1.56E-08	1227:1402
rs9291642	T	4	9616373	0.824:0.887	1.77[1.37-2.28]	1.03E-05	562:702	0.858:0.869	1.10[0.88-1.38]	3.92E-01	662:706	1.36[1.15-2.28]	3.63E-04	1224:1408
rs2305795	G	19	10087052	0.480:0.458	0.82[0.63-1.06]	1.31E-01	562:702	0.446:0.390	0.81[0.70-0.94]	4.70E-03	661:701	0.81[0.71-1.06]	1.35E-03	1223:1403
rs4810966	G	20	35703186	0.591:0.502	0.68[0.56-0.81]	2.44E-05	562:702	0.551:0.543	0.97[0.83-1.13]	6.81E-01	665:701	0.84[0.74-0.81]	2.52E-03	1227:1403
rs11085891	G	19	14395367	0.330:0.361	2.53[1.63-3.94]	3.85E-05	562:702	0.375:0.405	1.14[0.97-1.34]	9.94E-02	646:702	1.25[1.08-3.94]	3.22E-03	1208:1404
rs12148472	T	15	77018533	0.868:0.852	0.80[0.60-1.08]	1.41E-01	562:702	0.884:0.851	0.75[0.60-0.94]	1.17E-02	655:696	0.77[0.64-1.08]	3.77E-03	1217:1398
rs7553711	T	1	171398531	0.669:0.631	0.88[0.74-1.05]	1.57E-01	562:702	0.674:0.632	0.83[0.71-0.97]	2.24E-02	662:707	0.85[0.76-1.05]	8.19E-03	1224:1409
rs1338829	G	6	65198664	0.740:0.667	0.68[0.56-0.82]	7.49E-05	562:702	0.691:0.691	1.00[0.85-1.18]	9.87E-01	666:701	0.85[0.75-0.82]	1.08E-02	1228:1403
rs290183	G	11	85061310	0.764:0.828	1.55[1.25-1.92]	7.27E-05	562:702	0.804:0.800	0.98[0.81-1.18]	8.04E-01	664:710	1.19[1.03-1.92]	1.65E-02	1226:1412
rs473267	T	6	83936886	0.204:0.273	1.53[1.25-1.88]	4.57E-05	562:702	0.261:0.255	0.97[0.82-1.15]	7.51E-01	668:710	1.17[1.03-1.88]	1.88E-02	1230:1412
rs213038	C	1	21528791	0.153:0.215	1.63[1.30-2.06]	3.05E-05	562:702	0.188:0.180	0.95[0.78-1.15]	5.92E-01	660:704	1.19[1.02-2.06]	2.31E-02	1222:1406
rs1786783	T	18	33223187	0.787:0.852	1.61[1.28-2.03]	5.31E-05	562:702	0.846:0.834	0.91[0.74-1.12]	3.84E-01	664:707	1.17[1.00-2.03]	4.36E-02	1226:1409
rs2068662	G	12	94892386	0.088:0.042	0.39[0.26-0.58]	4.67E-06	562:702	0.062:0.080	1.30[0.97-1.73]	7.72E-02	669:707	0.87[0.68-0.58]	2.25E-01	1231:1409
rs7222250	T	17	37191995	0.593:0.559	0.40[0.26-0.62]	4.35E-05	562:702	0.555:0.562	1.03[0.88-1.20]	7.23E-01	662:706	0.93[0.80-0.62]	3.18E-01	1224:1408

rs#, SNP number; Allele, Effect allele; Chr, chromosome; Pos, position; AF_C1, allele frequency in controls in the discovery sample; AF_N1, allele frequency in narcoleptics in discovery samples; OR1[95%CI], odds ratio[95% confidence interval] discovery; p1, discovery P-value; n1, number of subjects in discovery (cases, controls); AF_C2, allele frequency in controls in the replication sample; AF_N2, allele frequency in narcoleptics in replication samples; OR2[95%CI], odds ratio[95% confidence interval] replication; p2, replication P-value; n2, number of subjects in replication (cases, controls); pMeta, meta-analysis P-value; nMeta, meta-analysis sample size (cases, controls).

and controls in each selected European country. As opposed to previous reports,^{3,20} in our population, fewer than 2% of narcolepsy patients are *DQB1*06:02* negative, confirming the extraordinary association between *DQB1*06:02* and narcolepsy (OR = 251). Although more than 98% of narcolepsy patients are *DQB1*06:02* positive in all European countries, substantial differences exist between different European control populations, with Italy and Spain having many fewer *DQB1*06:02* subjects than the Netherlands or Germany. Based on our observations (Table 2), *DQB1*06:02* has a positive predictive value of 65.68% (95%CI = 63.45%-67.86%) and a negative predictive value of 99.32% (95%CI = 98.95%-99.58%) for narcolepsy.

Given that *DQB1* allele frequencies vary in different populations, we tested if *DQB1* phenotypes of the general control populations in Europe indicate protection against narcolepsy. Several differences were found between European countries (e.g., *DQB1*03:01* is significantly protective in French and Italians but not in others), but meta-analysis in all European countries indicated that except for *DQB1*06:02*, all other *DQB1* phenotypes had higher frequencies in controls, and all except *DQB1*03:04*, *04:02*, *05:02*, and *06:04*, were significantly higher (Table 3). This finding confirms that only *DQB1*06:02* (present in 20% of the general European population) confers risk, and the remaining 80% carry a protective *HLA-DQB1* haplotype against narcolepsy. Since 20% of the general European population carry *DQB1*06:02*, the strong susceptibility allele, while only a small fraction (0.02-0.05%) is affected, other protective factors might be involved.

Accordingly, comparison between *DQB1*06:02* positive patients and controls revealed that *rs2858884* confers protection against narcolepsy, suggesting that *DQB1*06:02* positive controls can be protected by a *trans DQB1* allele. We first confirmed that *rs2858884* is strongly associated with several *DQB1* alleles, independent of the case or control status (Table 3). In order to disentangle the effect of protective haplotypes independent of *DQB1*06:02*, we analyzed the data by restricting the comparisons to heterozygous

Table 2—*DQB1*06:02* association in European countries

Country (case, control)	Case-DQB1+ N (%)	Control-DQB1+ N (%)	OR	P
DE (232, 296)	227 (97.84)	72 (24.3.2)	141.24	9.71E-26
CH (66, 473)	65 (98.48)	102 (21.56)	236.42	7.01E-8
NL (323, 469)	318 (98.45)	114 (24.31)	198.05	3.62E-30
PL (63, 197)	63 (100)	44 (22.33)	438.08	2.65E-09
SP (127, 1,174)	126 (99.21)	170 (14.48)	744.14	5.25E-11
FR (341, 499)	335 (98.24)	94 (18.84)	240.56	1.18R-37
IT (66, 433)	64 (96.97)	30 (6.93)	429.87	3.21E-16
Mantel-Haenszel (meta-analysis)	1,198 (98.36)	626 (17.68)	251.12	1.04E-120

DE, Germany; CH, Switzerland; NL, Netherlands; PL, Poland; SP, Spain; FR, France; IT, Italy; OR, odds ratio.

*DQB1*06:02* cases and controls. We first performed a univariate analysis to estimate the ORs using a general *DQB1*06:02* heterozygous background. A step-wise procedure was then employed, whereby in each step, carriers of the most significantly associated haplotype were removed and the association test (for each haplotype) was repeated for the remaining individuals. This analysis informed us which haplotypes confer protection independently of each other. The most protective *trans* alleles were *DQB1*06:03*, *DQB1*05:01*, *DQB1*06:09*, and *DQB1*02* (Table 4). Notably, the extent of their protective effects (ORs) were highly variable across different countries (Cochran's heterogeneity P-values < 10⁻¹³). To assess the effect of a second *DQB1*06:02* haplotype in *trans*, we have reanalyzed the data restricted to *DQB1*06:02* positive individuals (both heterozygous and homozygous). Several differences were found between European countries (e.g., *DQB1*02* is significantly protective in Dutch but not in others), but meta-analysis in all European countries indicated that homozygous *DQB1*06:02* doubled the risk of narcolepsy (Table S2).

Table 3—Mantel-Haenzel odds ratios and *rs2858884* association for *DQB1* phenotypes between cases and controls in European countries

<i>DQB1</i>	DE	CH	NL	PL	SP	FR	IT	MH	MH	<i>rs2858884</i>	
	232-296	66-473	323-469	63-197	127-1,174	341-499	66-433	OR	P	OR	P
02	0.73	0.54	0.37 ^d	0.53	0.58 ^a	0.49 ^c	0.49	0.51	1.02E-18	3.14	1.73E-51
03:01	0.69	0.5	0.88	0.71	0.65	0.59 ^b	0.45 ^a	0.65	3.48E-09	0.31	1.60E-23
03:02	0.23 ^c	0.6	0.54 ^a	1.41	0.34 ^a	0.54	0.78	0.49	1.52E-10	0.33	2.89E-09
03:03	0.24 ^a	0.34	0.48	0.47	0.39	0.26 ^a	0.9	0.37	2.06E-07	0.2	8.43E-05
03:04	0.44	1.44	0.99	0.95	0.86	0.48	1.26	0.57	3.28E-01	0	NA
04:02	1.03	0.6	0.93	0.37	0.35	0.8	0.14	0.69	2.55E-02	0.58	2.26E-02
05:01	0.29 ^c	0.35	0.24 ^d	0.21	0.29 ^b	0.33 ^c	0.08	0.27	2.71E-28	1	9.85E-01
05:02	0.48	0.85	1.21	0.4	1	0.74	1.37	0.85	2.76E-01	0.47	2.16E-03
05:03	0.66	0.41	0.31	0.63	1.35	0.48	0.1	0.5	2.01E-04	0.85	4.69E-01
06:01	0.19	0.42	0.42	0.57	0.27	0.06	0.27	0.18	1.03E-03	0.76	7.19E-01
06:02	8.07 ^d	8.92 ^d	7.80 ^d	7.45 ^d	11.83 ^d	9.66 ^d	27.08 ^d	9.33 ^d	6.23E-268	0.68	4.85E-03
06:03	0.12 ^c	0.3	0.12 ^c	0.11	0.05 ^a	0.16 ^c	0.16	0.13	2.52E-19	3.97	5.86E-27
06:04	0.85	0.8	0.81	0.35	0.97	1.11	0.39	0.84	2.38E-01	0.92	6.07E-01
06:09	0.44	3.77	0.59	0.41	0.18	0.07	1.06	0.23	5.45E-03	5.59	3.36E-07

^aP < 0.05; ^bP < 0.01; ^cP < 1E-3; ^dP < 1E-6, P values in bold survive Bonferroni correction. DE, Germany; CH, Switzerland; NL, Netherlands; PL, Poland; SP, Spain; FR, France; IT, Italy; MH, Mantel-Haenzel; OR, odds ratio. Numbers below country codes indicate number of patients-controls.

Table 4—Mantel-Haenzel odds ratios for *trans DQB1* alleles between *DQB1*06:02* heterozygous cases and controls in European countries

<i>DQB1</i>	DE 176-500	CH 53-102	NL 265-486	PL 59-149	SP 122-170	FR 298-352	IT 56-130	Univariate		Stepwise	
								MH OR	MH P	MH OR	MH P
02	1.37	0.97	0.65	0.44	1.45	1.08	0.74	0.95	5.96E-01	0.76	3.51E-03
03:01	1.29	0.96	1.63	2.07	1.71	1.75	0.96	1.5	8.19E-06	1.06	9.39E-01
03:02	0.59	1.39	1.47	1.96	0.6	0.89	1.94	1.03	8.35E-01	0.74	3.33E-02
03:03	0.51	0.49	1.89	0.66	0.52	0.49	4.59	0.81	3.24E-01	0.63	3.59E-02
03:04	0.88	NA	1.71	0.45	4.01	3.26	NA	1.45	5.99E-01	NA	NA
04:02	2.59	2.79	2.41	11.7	0.56	1.26	0.14	1.63	1.40E-02	1.17	4.39E-01
05:01	0.8	0.66	0.49	0.44	0.7	0.7	0.19	0.61	2.21E-04	0.56	1.43E-05
05:02	1.44	2.5	1.61	7.13	1.91	1.25	15.03	1.98	3.85E-04	1.60	1.71E-02
05:03	1.53	0.89	0.92	1.53	1.35	0.68	0.21	0.96	8.51E-01	0.71	1.19E-01
06:01	0.29	0.35	8.59	2.29	1.33	0.22	0.44	0.61	3.99E-01	0.44	1.70E-01
06:03	0.12	0.89	0.12	0.27	0.06	0.23	1.12	0.19	4.29E-11	0.19	4.29E-11
06:04	1.12	2.79	1.79	1.14	1.91	1.5	0.55	1.54	1.51E-02	1.07	7.31E-01
06:09	0.53	0.35	0.21	NA	0.26	0.1	4.59	0.24	6.98E-03	0.21	2.95E-03

P-values in bold survive Bonferroni correction. DE, Germany; CH, Switzerland; NL, Netherlands; PL, Poland; SP, Spain; FR, France; IT, Italy; MH, Mantel-Haenzel; OR, odds ratio; NA, not applicable. Numbers below country codes indicate number of patients-controls. Multivariate ORs and P-values were calculated in a stepwise fashion, where carriers of the most significant haplotypes are removed in each iteration.¹⁸

The next question is whether *DQB1*06:02* or another gene in its vicinity is different and unique to narcolepsy. *DQB1*06:02* was partially sequenced in 4 narcolepsy patients and no variation was observed.^{21,22} To exclude the possibility that a mutation occurred within this region in narcolepsy patients, we extracted the sequence corresponding to the full length of the HLA class II region from an ongoing exome sequencing project in 10 *DQB1*06:02* homozygous narcolepsy patients. No variant was found in any of the tightly linked *DRB1*15:01*, *DQAI*01:02*, or *DQB1*06:02* genes, confirming that the entire region is identical between narcolepsy patients and *DQB1*06:02* positive controls. Comparison among these 10 patients and the reference sequence indicated that the shared

and conserved haplotype includes *DRB5*, *DRB1*, *DQAI*, and *DQB1* genes (150kb, Figure S1).

DISCUSSION

Our GWAS replication confirms the complex HLA-*DQB1* involvement in susceptibility and protection from narcolepsy with cataplexy in Europe. As in most other autoimmune disorders, the overwhelming portion of risk and protection is found within the HLA region, and other common variants found through GWASs have little to negligible contribution. Narcolepsy is a rare disease and underdiagnosed, and large patient populations are not available to gain enough power to detect low effect size genetic variants. Our European

population is one of the largest, and we estimate that nearly 90% of European narcolepsy with cataplexy patients with complete diagnostic work-up and DNA available were included in the present study. Nevertheless, future efforts by including more patients might increase the statistical power to detect additional small effect size variants outside of the HLA region.

Previous studies in European ancestry, Japanese, Korean, and Chinese populations, have identified *DQB1*03:01* as a second susceptibility allele, while *DQB1*05:01*, *06:01*, and *06:03* were found to protect against narcolepsy.^{18,23,24} Here, we show that at least two other alleles (*DQB1*02*, and *DQB1*06:09*) also confer protection. The protective effects of *DQB1*05:01*, *06:01*, and *06:03* were interpreted in terms of allele competition.¹⁸ DQ molecules are heterodimers of α - and β -chains, encoded by *DQA1* and *DQB1* loci. The allele competition hypothesis posits that other DQ1 molecules than the susceptibility one (*DQ α *01:02/DQ β *06:02*) might compete and thus reduce the availability of susceptibility molecules. However, this hypothesis is not consistent with either an increased risk conferred by *DQB1*03:01* or decreased risk conferred by *DQB1*02* (which heterodimerize with *DQA1*05:01*). Additionally, our finding that *DQB1*06:09* also confers protection while heterodimerizing with the susceptibility *DQA1*01:02*, argues against the allele competition hypothesis. Because of a very tight linkage disequilibrium between *DQA1* and *DQB1*, the respective contribution of each locus is difficult to disentangle. Although *DQA1* typing was not available in our patients and controls, our finding that different *DQB1* alleles in tight linkage with the similar *DQA1* can both predispose and protect against narcolepsy constitutes an additional evidence that *DQB1* more than *DQA1* is the major locus associated with narcolepsy with cataplexy.

Overall, among 20% of the European general population who carry *DQB1*06:02* on one chromosome, on average one-third carries a neutral allele, one-third an additional risk allele, and one-third a protective allele on the other chromosome. Given the ORs in different countries in this study, it is expected that with larger populations, several other alleles with ORs ranging from 0.75 to 0.89, as found here, might turn out to be protective. Also, protective alleles may vary between populations as for instance *DQB1*06:01* is common and strongly protective in Japanese and Koreans,^{18,23} while it has a very low frequency in Caucasians. DQ molecules are encoded by *DQA1* and *DQB1* loci, mainly on the same chromosome (*cis*) but also on the opposite chromosome (*trans*). Accordingly, individuals heterozygous for *DQA1*05:01/DQB1*02:01* and *DQA1*03:01/DQB1*03:02* are at 5-fold higher risk for type 1 diabetes than those homozygous for either of the DQ variants,²⁵ clearly indicating the formation of highly susceptible *trans*-encoded molecules DQ8.5 (*DQA1*05:01/DQB1*03:02*) and DQ2.3 (*DQA1*03:01/DQB1*02:01*). Conversely, in narcolepsy, *DQA1*01:02/DQB1*06:02* and *DQA1*01:03/DQB1*06:03* heterozygotes are rare, probably because *trans* heterodimers encoded by *DQA1*01:03/DQB1*06:02* or *DQA1*01:02/DQB1*06:03* must be protective (note that such combinations are even found in *cis* in some populations, e.g., *DQA1*01:02/DQB1*06:03* in Slovenia and *DQA1*01:03/DQB1*06:02* in Iran, see <http://www.allelefrequencies.net/>).

One major difficulty in narrowing down the susceptibility/protective locus within the HLA class II region is the

well-documented large conserved extended HLA haplotypes (1 to 4 Mb), including several loci (most important ones being *DRB1*, *DQA1*, and *DQB1*). Nevertheless, comparisons in different ethnic groups strongly suggested that the minimum narcolepsy susceptibility region extends centromeric to *DRB1* locus from *DQA1* to *DQB1*.^{24,26,27} This observation is strengthened by the fact that many European ancestry *DRB1*15:01* negative narcolepsy patients still carry *DQA1*01:02-DQB1*06:02* (²⁷ and personal observation: four patients in the present study). Also, in the present study, *DQB1*06:04* and *DQB1*06:09* that are in almost complete linkage disequilibrium with *DRB1*13:02-DQA1*01:02*, confer opposing susceptibility or protection effects.

For a causal involvement, variants within a locus should result in susceptibility or protection only. In the present study, variants within each *DQB1*02*, *DQB1*03*, *05*, and *06* allelic group confer either susceptibility or protection, strongly supporting a causal *DQB1* involvement. *DQB1*02* found here as protective, is a common allele (between 17% and 25% carriers in European countries) and is the major susceptibility allele for type 1 diabetes, while *DQB1*06:02* is the major protective allele in this disease. Surprisingly (given the high prevalence of type 1 diabetes), there is not a single narcolepsy patient, so far reported, with type 1 diabetes, indicating an exclusive contribution of *DQB1*06:02* and *DQB1*02* to each condition, suggesting a complex contribution of *DQB1* locus, not only to narcolepsy but also to other HLA-associated disorders. It remains that *DQB1*06:02*, a common variant at the *DQB1* locus, confers an extraordinary risk (251-fold increase) to narcolepsy with cataplexy and almost all other *DQB1* common variants confer risk or protection with effect sizes from 2- to 5-fold. As opposed to all other common variants discovered by GWAS, which have small effects, HLA gene variants represent an exception in all HLA-associated disorders, and deserve renewed interest to understand how a common variant can be causally associated with a disease. In this effort, given its almost complete association with *DQB1*06:02*, narcolepsy with cataplexy is one of the best candidates.

Despite the fact that nearly 100% of narcolepsy with cataplexy patients are *DQB1*06:02* positive, HLA typing is disregarded in the diagnosis of narcolepsy with cataplexy, mainly because 20% of the general population is also positive (low specificity), and because of the cost of high resolution HLA typing. Instead, hypocretin deficiency (hypocretin-1 levels in the CSF < 110 pg/mL), which needs invasive lumbar puncture, is being considered as part of the definition of the condition (although performed in very few doubtful cases). Nevertheless, the almost 100% negative predictive value warrants HLA typing, not only in patients suspected of narcolepsy but especially in “at risk” populations. In this context, all narcolepsy patients, reported to date, who developed the disease after H1N1 vaccination were *DQB1*06:02* positive,¹²⁻¹⁵ thus at very high risk.

AUTHOR AFFILIATIONS

¹Center for Integrative Genomics (CIG) University of Lausanne, Lausanne, Switzerland; ²Center for Investigation and Research in Sleep (CIRS), Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; ³Center for Genomic Regulation (CRG), Barcelona, and Universitat Pompeu Fabra

(UPF), Barcelona, Spain; ⁴INSERM-1061, Montpellier, France; ⁵National Reference Network for Orphan Diseases (Narcolepsy and Idiopathic Hypersomnia), Department of Neurology, Guide-Chauliac Hospital, Montpellier, France; ⁶Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; ⁷Sleep-Wake Center SEIN, Heemstede, The Netherlands; ⁸Sleep Medicine Center 'Kempenhaeghe', Heeze, The Netherlands; ⁹Hephata-Clinic for Neurology, Schwalmstadt-Treysa, Germany; ¹⁰Neurology Service, Hospital Clínic de Barcelona, IDIBAPS, CIBERNED, Barcelona, Spain; ¹¹Sleep and Epilepsy Unit - Clinical Neurophysiology Department, Gregorio Marañón University Hospital, Madrid, Spain; ¹²Histocompatibility, Blood Center of the Community of Madrid, Madrid, Spain; ¹³National Reference Network for Orphan Diseases (Narcolepsy and Idiopathic Hypersomnia), Sleep disorders unit, Pitié-Salpêtrière Hospital, Paris, France; ¹⁴Department of Biomedical and NeuroMotor Sciences, University of Bologna and IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna Italy; ¹⁵Sleep Disorders and Research Center, Department of Psychiatry and Psychotherapy, University Hospital Regensburg, Regensburg, Germany; ¹⁶Institute of Psychiatry and Neurology, Department of Clinical Neurophysiology and Sleep Disorders Center, Warsaw, Poland; ¹⁷Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland; ¹⁸Pediatric Sleep Center, National Reference Network for Orphan Diseases (Narcolepsy and Idiopathic Hypersomnia), Robert Debré Hospital, Paris VII University, Paris, France; ¹⁹Department of Neurology, Faculty of Medicine, Safarikiensis University and Louis Pasteur Faculty Hospital Kosice, Kosice, Slovakia; ²⁰Department of Neurology, Innsbruck Medical University, Innsbruck, Austria; ²¹Unidad de Sueño, Servicio Neurofisiología Clínica, Hospital Universitario La Fe, Valencia, Spain; ²²Sleep Medicine, Barmelweid Clinic, Switzerland; ²³Servicio de Psiquiatría, Hospital Universitario Son Espases, Palma de Mallorca, Spain; ²⁴Department of Neurology, University Hospital Zurich, Switzerland; ²⁵Immunology Service, CDB, Hospital Clinic, Barcelona, Spain; ²⁶Department of Immunohaematology and Blood Transfusion, Leiden University Medical Centre, The Netherlands; ²⁷HLA Laboratory, Etablissement Français du Sang, Lyon, France; ²⁸Department of Immunogenetics, Institute of Hematology and Transfusion Medicine, Warsaw, Poland; ²⁹German National Bone Marrow Donor Registry, Ulm, Germany; ³⁰Lausanne Genomic Technologies Facility, Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland; ³¹Swiss Institute of Bioinformatics, Lausanne, Switzerland; ³²Laboratory of Immunogenetics and Transplant Biology, IME Foundation-Mediterranean Institute of Hematology, Roma, Italy; ³³National Reference Laboratory for Histocompatibility, Transplantation Immunology Unit, Department of Genetics and Laboratory Medicine, University Hospital Geneva, Geneva, Switzerland; ³⁴Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland; ³⁵Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

ACKNOWLEDGMENTS

Drs. Tafti and Hor contributed equally to the manuscript. The authors thank Paul Hörtnagl for HLA typing and Thomas

Mitterling for help in gathering patient's data from Austria. This work was performed on behalf of the European Narcolepsy Network (EU-NN).

DISCLOSURE STATEMENT

The study was largely funded by the University of Lausanne and partly supported by an EU-NN grant to M. Tafti. Additional support for this research was provided by the French Ministry of Research and Higher Education, Project Agence Nationale de la Recherche-07-MRAR (France), and PHRC 2007-P070138 (France) to Dr. Dauvilliers and Dr. Arnulf. Dr. Arnulf has participated in speaking engagements for UCB Pharma, consulted for UCB Pharma and Jazz Pharmaceuticals; and has been an investigator for studies by Bioprojet. Dr. Dauvilliers has participated in speaking engagements for and is on the advisory boards of UCB Pharma, Jazz, and Bioprojet. Dr. Frauscher has participated in speaking engagements for UCB Pharma. Dr. Geisler was an investigator for a study sponsored by Servier; participated in speaking engagement for UCB GmbH Germany; is a member of the German Neupro advisory board, UCB GmbH; and is a member of the Safety Review Board, Study HAROSA, sponsored by Bioprojet (France). Dr. Lecendreux has participated in speaking engagements for and is on the advisory boards of UCB Pharma, Jazz, and Bioprojet. Dr. Högl has participated in speaking engagements and or consulted for Mundipharma, UCB, Boehringer-Ingelheim, Glaxo-Smith-Kline, Jazz, Lundbeck Sanofi, and Respirationics; has received travel support from Vivisol and Habel Medizintechnik Austria; and has received research support to her institution from UCB. Dr. Frauscher has participated in speaking engagements or consulted for UCB Pharma and Mundipharma and she has received travel support from Vivisol and Habel Medizintechnik, Austria. Dr. Mayer has received research support from UCB Pharma; is on the speakers bureau for UCB, Cephalon, and S+Destin; consulted for UCB and Genzyme; and has participated in speaking engagements for UCB, Genzyme, Lundbeck, Cephalon, and Eli Lilly. Dr. Overeem has received research support through his institution from UCB Pharma; has served on the advisory boards of and received lecture fees from UCB, Novartis, and Boehringer Ingelheim (paid to his institution); and has received conference travel support from UCB. Dr. Tafti has received research support from and participated in speaking engagements for UCB Pharma. The other authors have indicated no financial conflicts of interest.

REFERENCES

1. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. *Lancet* 2007;369:499-511.
2. Luca G, Haba-Rubio J, Dauvilliers Y, et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. *J Sleep Res* 2013;22:482-95.
3. Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. *Sleep* 1997;20:1012-20.
4. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat Med* 2000;6:991-7.
5. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. *Lancet* 2000;355:39-40.
6. Hallmayer J, Faraco J, Lin L, et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. *Nat Genet* 2009;41:708-11.

7. Hor H, Kotalik Z, Dauvilliers Y, et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. *Nat Genet* 2010;42:786-9.
8. Kornum BR, Kawashima M, Faraco J, et al. Common variants in P2RY11 are associated with narcolepsy. *Nat Genet* 2011;43:66-71.
9. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. *J Clin Invest* 2010;120:713-9.
10. Kawashima M, Lin L, Tanaka S, et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. *Sleep* 2010;33:869-74.
11. Toyoda H, Tanaka S, Miyagawa T, Honda Y, Tokunaga K, Honda M. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. *Sleep* 2010;33:875-8.
12. Dauvilliers Y, Montplaisir J, Cochen V, et al. Post-H1N1 narcolepsy-cataplexy. *Sleep* 2010;33:1428-30.
13. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. *PLoS One* 2012;7:e33536.
14. Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. *Neurology* 2013;80:1315-21.
15. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. *Vaccine* 2013;31:1246-54.
16. Faraco J, Lin L, Kornum BR, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. *PLoS Genet* 2013;9:e1003270.
17. American Academy of Sleep Medicine. International Classification of Sleep Disorders, 2nd ed.: Diagnostic and Coding Manual. Westchester, IL: American Academy of Sleep Medicine, 2005.
18. Han F, Lin L, Li J, et al. HLA-DQ association and allele competition in Chinese narcolepsy. *Tissue Antigens* 2012;80:328-35.
19. Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. *Science* 2012;337:1190-5.
20. Rogers AE, Meehan J, Guilleminault C, Grumet FC, Mignot E. HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. *Neurology* 1997;48:1550-6.
21. Lock CB, So AK, Welsh KI, Parkes JD, Trowsdale J. MHC class II sequences of an HLA-DR2 narcoleptic. *Immunogenetics* 1988;27:449-55.
22. Uryu N, Maeda M, Nagata Y, et al. No difference in the nucleotide sequence of the DQ beta beta 1 domain between narcoleptic and healthy individuals with DR2,Dw2. *Hum Immunol* 1989;24:175-81.
23. Hong SC, Lin L, Lo B, et al. DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. *Hum Immunol* 2007;68:59-68.
24. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. *Am J Hum Genet* 2001;68:686-99.
25. Koeleman BP, Lie BA, Undlien DE, et al. Genotype effects and epistasis in type 1 diabetes and HLA-DQ trans dimer associations with disease. *Genes Immun* 2004;5:381-8.
26. Matsuki K, Grumet FC, Lin X, et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. *Lancet* 1992;339:1052.
27. Mignot E, Kimura A, Lattermann A, et al. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. *Tissue Antigens* 1997;49:329-41.

SUPPLEMENTAL MATERIAL

Table S1—Replication results for SNPs mapping within the DHSs or already reported as associated with narcolepsy, excluding patients included in Faraco et al.*

rs#	Allele	Chr	Pos	AF_C1:AF_N1	OR1[95%CI]	p1	n1	AF_C2:AF_N2	OR2[95%CI]	p2	n2	OR-Meta[95%CI]	pMeta	nMeta
rs2858884	C	6	32808061	0.219:0.106	0.50[0.37-0.68]	7.50E-06	306:702	0.161:0.109	0.64[0.49-0.84]	1.43E-03	358:697	0.57[0.47-0.68]	8.11E-08	664:1399
rs1154155	T	14	22072524	0.859:0.784	0.57[0.45-0.73]	7.03E-06	306:702	0.835:0.788	0.75[0.60-0.93]	1.02E-02	364:700	0.66[0.56-0.73]	8.48E-07	670:1402
rs9291642	T	4	9616373	0.824:0.881	1.68[1.26-2.24]	4.28E-04	306:702	0.858:0.875	1.16[0.89-1.53]	2.76E-01	364:706	1.38[1.13-2.24]	1.33E-03	670:1408
rs2305795	G	19	10087052	0.480:0.460	0.84[0.62-1.13]	2.39E-01	306:702	0.446:0.372	0.75[0.62-0.90]	1.61E-03	360:701	0.77[0.66-1.13]	9.48E-04	666:1403
rs4810966	G	20	35703186	0.591:0.501	0.67[0.55-0.83]	1.30E-04	306:702	0.551:0.555	1.02[0.85-1.22]	8.58E-01	366:701	0.85[0.74-0.83]	1.52E-02	672:1403
rs11085891	G	19	14395367	0.330:0.363	2.66[1.61-4.38]	1.23E-04	306:702	0.375:0.400	1.12[0.93-1.35]	2.45E-01	351:702	1.25[1.05-4.38]	1.43E-02	657:1404
rs12148472	T	15	77018533	0.868:0.858	0.86[0.62-1.19]	3.51E-01	306:702	0.884:0.864	0.83[0.64-1.09]	1.75E-01	359:696	0.84[0.68-1.19]	1.01E-01	665:1398
rs7553711	T	1	171398531	0.669:0.641	0.93[0.76-1.13]	4.47E-01	306:702	0.674:0.621	0.80[0.66-0.96]	1.55E-02	367:707	0.85[0.75-1.13]	2.24E-02	673:1409
rs1338829	G	6	65198664	0.740:0.675	0.71[0.57-0.88]	1.67E-03	306:702	0.691:0.722	1.16[0.95-1.42]	1.40E-01	363:701	0.92[0.80-0.88]	2.85E-01	669:1403
rs290183	G	11	85061310	0.764:0.823	1.51[1.18-1.93]	1.04E-03	306:702	0.804:0.788	0.91[0.73-1.13]	4.03E-01	363:710	1.14[0.97-1.93]	1.23E-01	669:1412
rs473267	T	6	83936886	0.204:0.272	1.58[1.25-1.98]	9.43E-05	306:702	0.261:0.253	0.96[0.78-1.18]	6.95E-01	368:710	1.20[1.03-1.98]	2.13E-02	674:1412
rs213038	C	1	21528791	0.153:0.216	1.63[1.27-2.10]	1.33E-04	306:702	0.188:0.207	1.13[0.90-1.41]	2.88E-01	360:704	1.33[1.12-2.10]	8.67E-04	666:1406
rs1786783	T	18	33223187	0.787:0.847	1.56[1.20-2.02]	9.06E-04	306:702	0.846:0.832	0.90[0.70-1.15]	3.99E-01	363:707	1.16[0.97-2.02]	9.75E-02	669:1409
rs2068662	G	12	94892386	0.088:0.044	0.39[0.24-0.62]	7.58E-05	306:702	0.062:0.089	1.46[1.05-2.03]	2.33E-02	369:707	0.95[0.72-0.62]	6.89E-01	675:1409
rs7222250	T	17	37191995	0.593:0.559	0.40[0.25-0.65]	2.37E-04	306:702	0.555:0.568	1.05[0.88-1.26]	5.79E-01	362:706	0.93[0.79-0.65]	4.37E-01	668:1408

rs#, SNP number; Allele, Effect allele; Chr, chromosome; Pos, position; AF_C1, allele frequency in controls in the discovery sample; AF_N1, allele frequency in narcoleptics in discovery samples; OR1[95%CI], odds ratio[95% confidence interval] discovery; p1, discovery P-value; n1, number of subjects in discovery (cases, controls); AF_C2, allele frequency in controls in the replication sample; AF_N2, allele frequency in narcoleptics in replication samples; OR2[95%CI], odds ratio[95% confidence interval] replication; p2, replication P-value; n2, number of subjects in replication (cases, controls); pMeta, meta-analysis P-value; nMeta, meta-analysis sample size (cases, controls). *Faraco J, Lin L, Kornum BR, et al. ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet 2013;9:e1003270.

Table S2—Mantel-Haenzel odds ratios for *trans* DQB1 alleles between DQB1*06:02 positive cases and controls in European countries

DQB1	DE 227-465	CH 65-95	NL 318-452	PL 63-134	SP 126-162	FR 335-323	IT 64-125	MH OR	MH P
02	1.07	0.82	0.57 ^a	0.48	1.47	1.03	0.66	0.87	1.07E-01
03:01	1	0.81	1.39	2.14	1.73	1.65	0.83	1.32	1.87E-03
03:02	0.49	1.19	1.29	2.04	0.61	0.86	1.75	0.94	6.33E-01
03:03	0.43	0.43	1.68	0.7	0.53	0.48	4.16	0.74	1.60E-01
03:04	0.73	NA	1.53	0.46	4.07	3.16	NA	1.35	6.68E-01
04:02	2.13	2.42	2.14	12.15	0.57	1.22	0.13	1.48	4.68E-02
05:01	0.66	0.57	0.43^a	0.46	0.72	0.68	0.17	0.56	1.13E-05
05:02	1.19	2.16	1.44	7.4	1.94	1.21	13.28	1.82^a	1.83E-03
05:03	1.27	0.78	0.82	1.6	1.38	0.66	0.19	0.89	5.75E-01
06:01	0.24	0.31	7.69	2.39	1.35	0.21	0.4	0.57	3.27E-01
06:02	3.85^d	3.07	2.66^c	0.61	0.66	1.38	3.57	2.22	7.74E-11
06:03	0.10^a	0.77	0.11^b	0.28	0.06	0.23^b	1.02	0.17	5.01E-12
06:04	0.92	2.42	1.58	1.19	1.94	1.45	0.5	1.4	5.91E-02
06:09	0.44	0.31	0.19	NA	0.27	0.09	4.16	0.22	4.15E-03

^aP < 0.05; ^bP < 0.01; ^cP < 1E-3; ^dP < 1E-6. P values in bold survive Bonferroni correction. DE, Germany; CH, Switzerland; NL, Netherlands; PL, Poland; SP, Spain; FR, France; IT, Italy; MH, Mantel-Haenzel; OR, odds ratio; NA, not applicable. Numbers below country codes indicate number of patients-controls.




Figure S1—Exome sequencing from 10 narcolepsy patients show variations on HLA genes on chromosome 6 (32,407,000-32,785,000). For each patient, exon coverage is represented in log scale. Positions with non-reference nucleotide compared to human genome hg19 are coloured in green for A, brown for G, blue for C and red for T. Genes non-homozygotes from reference are indicated with a pink box. Images were exported from Integrative Genomics Viewer [Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform* 2013;14:178-92].